Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Enhanced Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists in Patients With Melanoma

NCT04364230 is registered in ClinicalTrials.gov with Craig L Slingluff, Jr as lead sponsor.

NCT NCT04364230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04364230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Enhanced Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists in Patients With Melanoma
Lead sponsor
Craig L Slingluff, Jr
Phase
Phase 1/2
Overall status
Completed
Start date
September 28, 2020
Completion date
March 14, 2024
Enrollment
22 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, ocular melanoma, uveal melanoma